[{"id":"26365345-1570-49ca-8578-b67aa79e6819","acronym":"","url":"https://clinicaltrials.gov/study/NCT03397186","created_at":"2021-01-18T16:45:56.830Z","updated_at":"2024-07-02T16:36:55.814Z","phase":"Phase 2","brief_title":"Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma","source_id_and_acronym":"NCT03397186","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD8 • LAG3 • CTLA4 • CD4 • CCR5 • CXCR3","pipe":" | ","alterations":" CCR5 expression","tags":["CD8 • LAG3 • CTLA4 • CD4 • CCR5 • CXCR3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCR5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yondelis (trabectedin)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/19/2018","start_date":" 06/19/2018","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":" Completion: 05/01/2021","study_completion_date":" 05/01/2021","last_update_posted":"2019-09-10"}]